Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNSPNASDAQ:QLGNNASDAQ:RDHLNASDAQ:VINC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSPCNS Pharmaceuticals$0.88+5.0%$1.03$0.73▼$148.00$4.80M2.65698,883 shs240,222 shsQLGNQualigen Therapeutics$3.57+0.8%$3.69$2.85▼$29.44$2.64M0.01108,295 shs1,916 shsRDHLRedhill Biopharma$1.86+2.2%$1.96$1.71▼$20.28$4.26M4.23163,808 shs9,861 shsVINCVincerx Pharma$0.05-9.1%$0.06$0.04▼$17.17$262K1.75436,125 shs173,743 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSPCNS Pharmaceuticals0.00%+14.01%-15.89%-35.37%-98.89%QLGNQualigen Therapeutics0.00%-0.97%-5.83%-1.95%-58.57%RDHLRedhill Biopharma0.00%-2.11%+3.91%-30.08%-99.20%VINCVincerx Pharma0.00%-2.91%+3.09%-90.56%-99.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNSPCNS Pharmaceuticals1.52 of 5 stars3.32.00.00.01.60.00.6QLGNQualigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AVINCVincerx Pharma2.534 of 5 stars3.53.00.00.00.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSPCNS Pharmaceuticals 2.50Moderate Buy$25.002,744.14% UpsideQLGNQualigen Therapeutics 0.00N/AN/AN/ARDHLRedhill Biopharma 0.00N/AN/AN/AVINCVincerx Pharma 3.00Buy$40.0079,900.00% UpsideCurrent Analyst Ratings BreakdownLatest VINC, RDHL, CNSP, and QLGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025CNSPCNS PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSPCNS PharmaceuticalsN/AN/AN/AN/A$5.37 per shareN/AQLGNQualigen Therapeutics$4.98M0.53N/AN/A($20.31) per share-0.18RDHLRedhill Biopharma$8.04M0.53N/AN/A($3.66) per share-0.51VINCVincerx PharmaN/AN/AN/AN/A$10.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSPCNS Pharmaceuticals-$14.86M-$3,748.50N/A∞N/AN/A-385.41%-193.20%8/13/2025 (Estimated)QLGNQualigen Therapeutics-$13.42MN/A0.00∞N/AN/AN/A-424.18%7/1/2025 (Estimated)RDHLRedhill Biopharma-$8.27MN/A0.00∞N/AN/AN/AN/AN/AVINCVincerx Pharma-$40.16M-$20.60N/AN/AN/AN/A-248.33%-132.73%8/6/2025 (Estimated)Latest VINC, RDHL, CNSP, and QLGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNSPCNS PharmaceuticalsN/A-$1.58N/A-$1.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSPCNS PharmaceuticalsN/A4.944.94QLGNQualigen TherapeuticsN/A0.520.52RDHLRedhill BiopharmaN/A0.540.37VINCVincerx PharmaN/A2.172.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSPCNS Pharmaceuticals14.02%QLGNQualigen Therapeutics3.18%RDHLRedhill Biopharma7.20%VINCVincerx Pharma44.02%Insider OwnershipCompanyInsider OwnershipCNSPCNS Pharmaceuticals0.07%QLGNQualigen Therapeutics1.80%RDHLRedhill Biopharma6.81%VINCVincerx Pharma15.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNSPCNS Pharmaceuticals55.46 million5.46 millionNot OptionableQLGNQualigen Therapeutics50740,000723,000Not OptionableRDHLRedhill Biopharma2102.29 million2.14 millionNo DataVINCVincerx Pharma605.23 million1.89 millionNot OptionableVINC, RDHL, CNSP, and QLGN HeadlinesRecent News About These CompaniesVincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution ProposalJune 18, 2025 | globenewswire.comVincerx Pharma announces plan to delist from NasdaqApril 18, 2025 | markets.businessinsider.comVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SECApril 17, 2025 | finance.yahoo.comVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SECApril 17, 2025 | globenewswire.comVincerx's final merger attempt collapses, leaving ADC biotech to wind downApril 9, 2025 | fiercebiotech.comFVincerx terminates letter of intent with Global Digital, initiates wind downApril 9, 2025 | markets.businessinsider.comFinancially struggling drugmaker's potential rescue falls apart. It now will wind downApril 9, 2025 | bizjournals.comVincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down ActivitiesApril 8, 2025 | globenewswire.comVincerx Pharma announces non-binding LOI for Qumulus AI combinationMarch 18, 2025 | markets.businessinsider.comVincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | finanznachrichten.deVincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisisMarch 18, 2025 | fiercebiotech.comFVincerx Pharma Shares Soar on Proposed Merger with Global Digital HoldingsMarch 18, 2025 | marketwatch.comVincerx Pharma, Inc. Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | quiverquant.comQVincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | globenewswire.comCash-strapped Vincerx left mulling future after Oqory reverse merger falls apartMarch 3, 2025 | fiercebiotech.comFVincerx Pharma announces termination of reverse merger term sheetMarch 1, 2025 | markets.businessinsider.comVincerx Pharma Terminates Reverse Merger Deal With OqoryMarch 1, 2025 | marketwatch.comVincerx Pharma, Inc. Terminates Reverse Merger Agreement and Will Explore Strategic AlternativesFebruary 28, 2025 | quiverquant.comQVincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic AlternativesFebruary 28, 2025 | globenewswire.comVINC stock touches 52-week low at $1.3 amid market challengesFebruary 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVINC, RDHL, CNSP, and QLGN Company DescriptionsCNS Pharmaceuticals NASDAQ:CNSP$0.88 +0.04 (+5.02%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.89 +0.01 (+1.14%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Qualigen Therapeutics NASDAQ:QLGN$3.57 +0.03 (+0.82%) Closing price 06/27/2025 03:55 PM EasternExtended Trading$4.02 +0.45 (+12.64%) As of 09:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.Redhill Biopharma NASDAQ:RDHL$1.86 +0.04 (+2.20%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$1.90 +0.03 (+1.88%) As of 08:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Vincerx Pharma NASDAQ:VINC$0.05 -0.01 (-9.09%) As of 06/27/2025 03:59 PM EasternVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
